Sinusoidal obstruction syndrome: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatic sinusoidal obstruction syndrome}} | {{Hepatic sinusoidal obstruction syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{HS}} | ||
{{SK}} Hepatic veno-occlusive disease; Veno-occlusive disease of the liver; Obliterative endophlebitis; blue liver syndrome; toxic sinusoidal injury | {{SK}} Hepatic veno-occlusive disease; Veno-occlusive disease of the liver; Obliterative endophlebitis; blue liver syndrome; toxic sinusoidal injury | ||
==[[Sinusoidal obstruction syndrome overview|Overview]]== | ==[[Sinusoidal obstruction syndrome overview|Overview]]== | ||
Latest revision as of 03:38, 12 February 2018
Template:Hepatic sinusoidal obstruction syndrome Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Synonyms and keywords: Hepatic veno-occlusive disease; Veno-occlusive disease of the liver; Obliterative endophlebitis; blue liver syndrome; toxic sinusoidal injury
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Sinusoidal obstruction syndrome from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Diagnostic criteria | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies